TAPI-1

• Description :

  TAPI-1 is a TACE (ADAM17) inhibitor and blocks the shedding of several cell surface proteins[1]. TAPI-1 is also a metalloproteinase (MMP) inhibitor[2].

• UNSPSC :

  12352005

• Hazard Statement :

  H301

• Target :

  MMP

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/TAPI-1.html

• Purity :

  99.36

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(N[C@@H](CC1=CC=C2C=CC=CC2=C1)C(N[C@@H](C)C(NCCN)=O)=O)[C@H](CC(C)C)CC(NO)=O

• Molecular Formula :

  C26H37N5O5

• Molecular Weight :

  499.60

• Precautions :

  H301

• References & Citations :

  [1]Bae EH, et al. Tumor necrosis factor α-converting enzyme inhibitor attenuates lipopolysaccharide-induced reactive oxygen species and mitogen-activated protein kinase expression in human renal proximal tubule epithelial cells. Korean J Physiol Pharmacol. 2018 Mar;22 (2) :135-143.|[2]Moss ML, et al. Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation. Mediators Inflamm. 2017;2017:9673537.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [163847-77-6]